|Articles|July 29, 2013
Mechanism of Action: Afatinib (BIBW 2992)
Afatinib is an FDA-approved pan-HER inhibitor for the first-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.
Advertisement
Afatinib (Gilotrif), previously known as BIBW 2992, is an FDA-approved pan-HER inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Ateganosine Plus Cemiplimab Shows 90.5% Disease Control in Pretreated NSCLC
2
After the First TKI Fails: Sequencing Challenges in ROS1-Positive NSCLC
3
FDA Clears IND for Next-Gen Oncolytic Virus UGN-501 in NMIBC
4
CMS Proposes Cut to 340B Drug Payments in 2027 Outpatient Rule
5